S&P Futures
4,006.75 -13.00 (-0.32%) Dow Futures
32,084.00 -36.00 (-0.11%) Nasdaq Futures
12,314.75 -68.00 (-0.55%) Russell 2000 Futures
1,783.50 -6.00 (-0.34%) Crude Oil
109.99 -0.50 (-0.45%) Gold
1,799.30 -8.90 (-0.49%)
Inventiva S.A. (IVEVF)
Chart Events
Performance Outlook
| Previous Close | 13.64 |
| Open | 13.64 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 13.64 - 13.64 |
| 52 Week Range | 10.84 - 13.64 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 555.73M |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.37 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.09 |
- GlobeNewswire
Inventiva secures a €50 million credit facility from the European Investment Bank
This credit facility is intended to support the progress and expansion of Inventiva’s pipelineThe credit facility consists of two tranches of €25 million eachCredit agreement is part of the European Investment Bank’s strategy to support biotech companies developing a high-level of expertise in various therapeutic areas with significant unmet medical needs Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinic
- GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2022
Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : www.inventivapharma.com DateNumber of Shares Outstanding Total voting rights, gross (1) Total voting rights, net (2)April 11, 202240 873 55152 801 40952 741 093 The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the b
- GlobeNewswire
Combined General Meeting of May 19, 2022 - Availability of the preparatory documents
Daix (France), Long Island City (New York, United States), April 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of May 19, 2022. Shareholders are invited to participate in the ann
